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Background 
Rheumatic diseases (RD) and malignancies may be 
connected to each other in different ways. It has previously 
been shown, that RD can be a primary manifestation of an 
underlying cancer as a paraneoplastic syndrome (PNS). RD 
are related with increased incidence of different malignancies 
due to the characteristic of the disease or as a result of drug 
therapy, for instance immunosuppressive agents and tumor 
necrosis factor inhibitors [1]. 
Paraneoplastic rheumatic syndromes (PRS) are 
rheumatologic diseases that are triggered by a malignant 
disease. Symptoms of PRS can not be explained by the 
anatomical location of the tumor or metastases, and they 
often remit following treatment of the underlying disease [2]. 
The pathogenesis of PRS is complex and not fully 
understood. Recent research has shown that certain tumors 
produce hormones, peptides or cytokines that can interact 
with the immune system and results in various clinical 
manifestations of the musculoskeletal system [3]. The PNS 
may be the patient's primary complaint and occurs up to two 
years before the underlying cancer is diagnosed. 
Non-Hodgkin's lymphoma is often associated with rheumatic 
disease [1, 4]. 
 As a result of improvement in diagnostic and therapeutic 
technique the number of patients with cancer and probably 
the incidence of PRS will increase, which can affect the 
clinical course and management of the disease. Management 
of PRS consists of treatment of underlying malignancy and 
standard therapy of rheumatic syndrome [2]. 
The purpose of this case report is to emphasize the 
challenging elements in the differential diagnosis within 
rheumatology, and to describe a newly defined group of very 
aggressive lymphomas, so-called double-hit lymphoma 
(DHL), which are characterized by cytogenetic translocation 
of both MYC and BCL2. We report a case history of a 
63-year-old woman with hip pain as a PRS. 
Case report 
A 63-year-old woman referred to the rheumatology 
outpatient clinic with a history of a persistent four weeks 
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right-sided hip pain. The pain was constant and severe. X-ray 
of the hip and pelvis were normal. Objectively, there was no 
sign of arthritis, except pain-related limitation of motion. 
Laboratory work-up showed leukocytes: 10.4 x 109 / l, 
platelets: 110 × 109 / l, Hb: 5.6 mmol/l, C-reactive protein: 
47 mg/l (normal range: <10 mg / l), ionized calcium: 1.22 
mmol/l (normal range: 1.19-1.29mmol/l), Lactate 
dehydrogenase (LDH): 958 U/l (normal range: 105-205) and 
erythrocyte sedimentation rate: 17. Immunological test 
values including Immunoglobulin (Ig) M, IgG and IgA were 
within normal limits.  
Four days later she was admitted to the local hospital with 
a preliminary diagnosis of cholecystitis. Ultrasound of 
abdomen identified supracapsular process on the right kidney 
upper pole. CT urography demonstrated 3 pathologically 
enlarged lymph nodes located centrally in the 
retroperitoneum. A biopsy of a subcutaneous nodule was 
performed. Pathology results revealed aggressive 
medium-sized B-cell lymphoma between diffuse large B-cell 
lymphoma and Burkitt lymphoma (Figure 1) with high 
mitotic activity (starry-sky appearance). 
Immunohistochemical staining of tumor cells were positive 
for CD20, CD10, PAX5, FOX P1, MUM1, lambda, MYC, 
BCL2 and Ki 67 (with 100% proliferation rate) and negative 
for CD21, BCL6, GCET1, TdT, EBER, CD3, CD5 and 
kappa. Flowcytometry analysis showed 59.4% B-cells with 
expression of CD20, CD22, CD79b, CD24, CD19 and 
lambda. In addition, these cells were weakly positive for 
CD10. 
FISH technique detected translocation of MYC, BCL2, 
IGH and no translocation of the BCL6 gene. These findings  
Table 1. Ann Arbor staging 
Stage I Indicates that the cancer is located in a single region, usually one 
lymph node and the surrounding area. Stage I often will not have 
outward symptoms. 
Stage II Indicates that the cancer is located in two separate regions, an 
affected lymph node or organ and a second affected area, and 
that both affected areas are confined to one side of the 
diaphragm - that is, both are above the diaphragm, or both are 
below the diaphragm. 
Stage III Indicates that the cancer has spread to both sides of the 
diaphragm, including one organ or area near the lymph nodes 
or the spleen. 
Stage IV Indicates diffuse or disseminated involvement of one or more 
extralymphatic organs, including any involvement of the liver, 
bone marrow, or nodular involvement of the lungs. 
A or B The absence of constitutional (B-type) symptoms is denoted by 
adding an "A" to the stage; the presence is denoted by adding a 
"B" to the stage. 
S Is used if the disease has spread to the spleen. 
E Is used if the disease is "extranodal" (not in the lymph nodes) 
or has spread from lymph nodes to adjacent tissue. 
X Is used if the largest deposit is >10 cm large ("bulky disease"), 
or whether the mediastinum is wider than 1/3 of the chest on a 
chest X-ray. 
 
are diagnostic of underlying double-hit lymphoma (DHL). 
Staging investigations showed widespread disease with 
involvement of several lymph node regions, bone marrow, 
subcutaneous tissue and myocardium equal to Ann Arbor 
staging 4B [5]. (Table 1) .Intensive courses of chemotherapy 
with high doses of Methotrexate, Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine were started 
with supplemented high dose Prednisolone, and a month later 
hip pain disappeared. Patient achieved complete remission 
after chemotherapy, but the disease relapsed shortly after in 
central nervous system (Figure 2). The patient died after a 
total of 11 months disease. 
Discussion 
PNS is relatively rare and occurs in up to 8% of all cancer 
patients [2]. It is known that some rheumatological diseases 
are associated with increased incidence of cancer. In the 
literature there are underlying malignancies in 10-25% of 
cases with dermato-/polymyositis, and up to 90% in 
hypertrophic osteoarthropathy (HOA). Therefore clinicians 
have to pay special attention to the symptoms of the 
above-mentioned diseases. 
HOA is divided into primary/hereditary and secondary 
forms. The secondary form is commonly related with lung 
cancer, bone metastasis, nasopharyngeal carcinoma and 
rhabdomyosarcoma. Diagnosis of hypertrophic 
osteoarthropathy can be made by physical examination and 
radiographic evaluation. Subsequent treatment of the 
underlying cancer improves the condition. [1, 2]. 
There is an association between ovarian, lung, breast, 
gastrointestinal system, non-Hodgkin lymphomas, prostate  
Figure 1. Subcutaneous biopsy shows diffuse infiltration of the 
medium-sized lymphoid cells with a high mitotic activity (A). 
The tumor cells expressing CD20 (B), myc (C) and BCL2 (D) [12] 
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Table 2. Different paraneoplastic rheumatic syndromes and 
their association with underlying cancer 
Hypertrophy osteoarthropathy Lung cancer, metastasis to bone, 
nasopharyngeal carcinoma, 
rhabdomyosarcoma  
Dermato-/polymyositis Ovarian, lung, breast, 
gastrointestinal system, 
non-Hodgkin lymphomas, prostate 
and nasopharynx (Asian population) 
Vasculitis Lymphoproliferative and 
myeloproliferative disorders 
Carcinomatous polyarthritis Breast, colon, lung and ovarian 
lymphoproliferative disorders. 
Palmar fasciitis Ovarian (most common), stomach, 
pancreas, lung and colon 
Reflex-sympathetic dystrophy 
syndrome 
(chronic regional pain syndrome 
type II) 
Pancoast tumor of the lung, 
malignancies that infiltrates the 
stellate ganglion or brachial plexus 
Erythromelalgia Myeloproliferative disorders 
especially Polycythemia Vera and 
essential trombocytosis 
Polymyalgia Rheumatica (PMR) Kidney, lung, colon cancer and 
multiple myeloma 
Amyloidosis Multiple myeloma, lymphomas and 
carcinomas 
Digital necrosis - Raynaud’s 
syndrome 
Solid tumors (most frequent 
stomach, lung, ovarian) and 
lymphoproliferative disorders. 
Remitting seronegative symmetric 
synovitis 
with pitting edema (RS3PE) 
Lymphoma, myelodysplastic 
syndrome, adenocarcinoma 
Multicentric reticulohistiocytosis Carcinoma of the lung, stomach, 
breast, cervix, colon and ovary 
Panniculitis Hematologic malignancies or 
pancreatic cancer. 
Lupus-like syndromes Ovarian carcinoma, hairy-cell 
leukemia and breast carcinoma 
Scleroderma-like syndrome Adenocarcinoma and carcinoid 
tumor 
Sjögren’s syndrome Lymphoproliferative 
disorders(non-Hodgkin’s 
lymphoma), lymphoma of 
mucosal-associated lymphoid tissue 
(MALT), Waldenström’s 
macroglobulinemia, chronic 
lymphocytic leukemia and multiple 
myeloma 
Rheumatoid arthritis (RA) Lymphoproliferative disorders, lung 
cancer 
Systemic lupus erythematosus 
(SLE) 
Lymphoproliferative disorders, 
gynecologic malignancies 
Systemic sclerosis Lung, breast, esophagus and skin 
Paget’s disease of bone Osteosarcoma (under 1%) 
 
and nasopharynx (Asian population) malignancies and 
dermato-/polymyositis [1, 6]. Ovarian cancer is the most 
common cancer in patients diagnosed with paraneoplastic 
dermatomyositis [7]. The highest risk for malignancy is 
within the first year of disease and it decreases gradually, but 
the risk still remains high compared to the general 
population. Thorough physical examination and laboratory 
test can lead to a diagnosis; although definite diagnosis is 
based on skin or muscle biopsy. Further imaging studies such 
as ultrasound, mammography and PET/CT Scan are helpful 
to determine the underlying cancer in specific cases. 
Paraneoplastic dermatomyositis responds poorly to 
corticosteroid treatment. Treatment of the primary cancer is a 
mainstay and can cause symptom regression [1, 6, 7].  
Vasculitis can occur as PRS especially in association with 
haematological cancers, but the prevalence is not exactly 
known (approximately 3-8%) [8]. Leukocytoclastic vasculitis 
is the most frequent finding in histopathological exam, which 
is responsible for 30-40% of all paraneoplastic vasculitis 
cases [8]. The etiology of paraneoplastic vasculitis is not 
clear. Paraneoplastic vasculitis responds poorly to 
conventional treatment. Other paraneoplastic rheumatic 
syndromes such as Raynaud's phenomenon, erythema 
nodosum and non-specific symptom as arthralgia, are 
reported less frequently in a few case reports. (Table 2) [1-4, 8]. 
In recent years DHL has been identified as a group of 
extremely aggressive B-lymphomas with often poor 
treatment response and consequently short survival. Patients 
almost always present with advanced disease with 
involvement of extranodal sites. Poor prognostic factor 
associated with double hit lymphoma include increased LDH 
level, involvement of central nervous system/ bone marrow 
and a high international prognostic index score which 
primarily present in most of the cases. This case report 
illustrates a fulminant clinical course, which is characteristic 
of this type of lymphoma [9-10] . 
Figure 2. T1-weighted coronal sequence after Gd-contrast 
shows a 17x12x12 mm contrast enhancing tumor in the right 
temporal lobe. 
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In rheumatologic studies it may be difficult for the 
clinicians to differentiate between underlying malignancy 
and primary rheumatologic disease, because the clinical 
manifestations are identical. But attention should be given 
when there are sudden occurrence of symptoms, unusual 
joint involvement, atypical age at disease onset and lack of 
response to therapy [4, 11]. 
There is no consensus on when a patient with 
rheumatological symptoms should be screened for possible 
underlying cancer. It is not economically justifiable to start 
performing a comprehensive examination for occult cancer, 
where it could be PRS in every case, but it should be part of 
the differential diagnosis in patients showing an atypical 
course, since early diagnosis of PRS will increase the 
patient's quality of life and chance of survival. 
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